Navigation Links
Signalife Announces Webcast
Date:4/11/2008

GREENVILLE, S.C., April 11 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) has confirmed that it has filed its form 10-KSB, and the company's Chairman and Chief Executive Officer, Dr. Lowell T. Harmison, has scheduled a webcast on April 14, 2008, at 10:00 a.m. EDT.

Dr. Harmison stated: "Now that Signalife has closed filing the company's form 10-KSB and the Company is manufacturing and shipping product, I am pleased to provide direction on new contracts, pending orders and production, various product initiatives (from the Fidelity 100 to the prospective industry-wide application of the Fidelity 1000 module), and the Athletes For Life partnership, as well as such issues as the Company's immediate, positive financial prospects as well as several other initiatives that have now been completed. The webcast will be broadcast from a studio and will be attended by representatives of Athletes for Life Foundation and selected invited members of the business press. To the extent time permits, I will answer questions following my presentation. I urge all persons following the company to view the webcast."

You may access the webcast either directly at http://www.videonewswire.com/event.asp?id=47313, or through Signalife's webpage at http://www.signalife.com, and will have the opportunity to submit written questions over the internet. You may also view or review the webcast for a 12-month period at the same website addresses (please allow several hours for Signalife to effectuate this archival link). All individuals viewing the original webcast or any replay are reminded that the webcast is copyrighted by the company and cannot be recorded or rebroadcast without the company's express written consent.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at http://www.signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

In this news release we make a number of statements, referred to as "forward-looking statements", which are intended to convey our expectations or predictions regarding the occurrence of possible future events or the existence of trends and factors that may impact our future plans and operating results. Any statements in this news release that are not statements of historical fact maybe considered to be forward-looking statements. These forward-looking statements are derived, in part, from various assumptions and analyses we have made in the context of our current business plan and information currently available to us and in light of our experience and perceptions of historical trends, current conditions and expected future developments and other factors we believe to be appropriate in the circumstances. You can generally identify forward-looking statements through words and phrases such as "seek", "anticipate", "believe", "estimate", "expect", "intend", "plan", "budget", "project", "may be", "may continue", "may likely result", and similar expressions. Each forward-looking statement should be read in context with, and with an understanding of, the various other disclosures concerning our company and our business made in this news release as well as other public reports we file with the SEC, as they may be amended. You should not place undue reliance on any forward-looking statement as a prediction of actual results or developments. We are not obligated to update or revise any forward-looking statement contained in this news release to reflect new events or circumstances unless and to the extent required by applicable law.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AMEX Notifies Signalife That It Has Accepted Signalifes Plan of Compliance
2. Signalife Sees Accretive Purchase and Financial Commitments
3. Signalife Wins Second Frost & Sullivan Technology Award
4. Signalife & Athletes Foundation Dispatch Mobile Health Center to Super Bowl
5. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
6. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
7. U.S. Patent 7,299,083 Awarded to Signalife
8. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
9. Signalife Continues to Procure Purchase Orders, Revenues
10. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
11. Signalife Receives Another $3.3 Million Sales Orders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... NORWALK, Conn. , Dec. 2, 2016  The ... research presentations from the MMRF CoMMpass Study SM —the ... and accelerating precision medicine in multiple myeloma—will be presented ... (ASH) Annual Meeting & Exposition in San ... are helping to optimize treatment strategies, as well as ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... value of DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic ... Symposium. Using molecular test results from tumors with previously documented positive, negative, ...
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, ... on their recent FDA Class II 510(k) clearance for their flagship medical device, ... commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While other companies ...
(Date:12/2/2016)... leader in rapid infectious disease tests, introduced the Company,s newest product, the INSTI HIV ... http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , bioLytical was invited by the Clinton Health ... Self Test to 350 pharmacy representatives in Nairobi and Mombasa, ...
Breaking Biology Technology:
(Date:11/30/2016)... WARSAW, Poland , Nov. 30, 2016 Not many of ... the most crucial aspects of recovery so we need to do it well. Inadequate ... including heart problems, high blood pressure, stroke, diabetes, and even cancer. Maybe ... find a Christmas present that could help them to manage their sleep quality? ... ...
(Date:11/29/2016)... Lithuania , Nov. 29, 2016 /PRNewswire/ ... biometric identification and object recognition technologies, today ... (SDK) for fingerprint recognition solutions that run ... a fingerprint template using less than 128KB ... in compact devices that have limited on-board ...
(Date:11/24/2016)... IRVINE, Calif. , Nov. 23, 2016 ... help endurance athletes and their trainers non-invasively measure ... Variability Index, Pulse Rate, and Respiration Rate in approximately ... Ember enables users easy and immediate access to key ... as part of a training regimen. ...
Breaking Biology News(10 mins):